News Focus
News Focus
icon url

Hosai

03/29/26 4:46 PM

#516502 RE: Investor2014 #516500

Well FDA rejected Donanenabs accelerated approval application based on their phase 2 because more data was needed. It clearly didn't mean Donanemab was worthless or doomed that the regulator refused to recommend approval.

https://investor.lilly.com/news-releases/news-release-details/us-food-and-drug-administration-issues-complete-response-0